Abbott Laboratories (NYSE:ABT) Stock Sentiment Increases to 0.91

May 16, 2018 - By Palma Niemeyer

Abbott Laboratories (NYSE:ABT) Corporate Logo

“Big money” Positions

“Big money sentiment for Abbott Laboratories (NYSE:ABT) in Q4 2017 increased to 0.91, SEC filings reveal. So its up 0.04, from 2017Q3’s 0.87. 553 hedge funds increased and started new holdings, while 610 sold and reduced equity positions in Abbott Laboratories so the sentiment has increased. Funds own 1.22 billion shares, up from 1.21 billion shares in 2017Q3. Funds holding Abbott Laboratories in top 10 changed to 58 from 59 for a decrease of 1. In total 52 funds closed positions, 558 reduced and 430 increased. Also 123 funds bought new Abbott Laboratories stakes.

Significant Abbott Laboratories Shareholders

Sector Gamma As owns 1.08 million shares in Abbott Laboratories as of Q4 2017. As of Q4 2017, 161,230 shares of Abbott Laboratories are owned by Brandywine Trust Co. Furthermore, Poplar Forest Capital Llc reported 1.21 million shares in Abbott Laboratories equivalent to 5.49% of its fund portfolio. Prentiss Smith & Co Inc revealed 192,863 shares position in Abbott Laboratories. The Delaware-based fund Green Valley Investors Llc holds 1.96 million shares or 5.32% of their fund portfolio.

Abbott Laboratories manufactures and sells health care products worldwide.The firm is worth $106.60 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon.The P/E ratio is 226.04. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

ABT hit $60.805 during the last trading session after $0.265 change.Currently Abbott Laboratories is uptrending after 34.85% change in last May 16, 2017. ABT has 2.26M shares volume. ABT outperformed by 23.30% the S&P500.

Abbott Laboratories (NYSE:ABT)’s quarterly earnings will be announced on July, 19., Zacks reports. Analysts forecast 14.52 % diference or $0.71 from the $0.62 EPS from 2017. If ABT’s EPS is $0.71 the profit will reach $1.24 billion for 21.41 P/E. Last quarter $0.59 earnings per share was reported. Analysts sees 20.34 % EPS growth this quarter.

Foyston Gordon And Payne accumulated 12,843 shs. Virtus Advisers holds 32,378 shs or 0.2% of its capital. Lincoln National invested 0.09% of its capital in Abbott Laboratories (NYSE:ABT). Winslow Evans And Crocker Incorporated invested 0.53% of its capital in Abbott Laboratories (NYSE:ABT). Ballentine Ptnrs Limited Liability Corp holds 8,923 shs. Schafer Cullen Mngmt Inc owns 66,960 shs. Pension Ser reported 1.41M shs. Nadler Grp has invested 0.21% in Abbott Laboratories (NYSE:ABT). Iguana Healthcare Ltd reported 75,000 shs stake. Lmr Llp has invested 0.13% in Abbott Laboratories (NYSE:ABT). Cape Ann Financial Bank holds 16,442 shs or 1.18% of its capital. Boston Private Wealth Ltd Liability Corporation accumulated 538,962 shs. Eqis Capital Inc holds 0.05% or 17,580 shs in its capital. Allen Inv Mgmt Limited Liability has invested 0.03% in Abbott Laboratories (NYSE:ABT). Norris Perne And French Ltd Liability Partnership Mi holds 1.45% or 175,104 shs.

Abbott Laboratories had 20 selling transactions and 1 buying transaction since December 14, 2017. This’s net activity of $23.69 million. Shares for $27,213 were sold by PEDERSON MICHAEL J on Friday, February 16. On Wednesday, February 28 905 shs were sold by Salvadori Daniel Gesua Sive, worth $53,369. 6,284 shs valued at $375,381 were sold by Contreras Jaime on Wednesday, February 28. On Friday, February 16 Watkin Jared also sold $17,609 worth of Abbott Laboratories (NYSE:ABT). 11,106 shs were sold by Fussell Stephen R, worth $667,804. BIRD ROGER also sold $96,728 worth of Abbott Laboratories (NYSE:ABT) on Wednesday, February 28.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

A total of 14 analysts rate Abbott Laboratories (NYSE:ABT) as follows: 12 “Buy”, 2 “Hold” and 0 “Sell”. Тherefore 86% are bullish. (NYSE:ABT) has 20 ratings reports on 16 May 2018 according to StockzIntelligence. In Tuesday, December 12 report BMO Capital Markets upgraded it to “Outperform” rating and $6 target. In Thursday, January 25 report Barclays Capital maintained it with “Overweight” rating and $70 target. On Monday, January 22 the company was downgraded by BTIG Research. On Tuesday, January 30 the firm has “Neutral” rating by Citigroup given. On Thursday, January 25 the rating was maintained by Morgan Stanley with “Overweight”. On Thursday, January 25 Wells Fargo maintained Abbott Laboratories (NYSE:ABT) with “Outperform” rating. On Wednesday, January 24 RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating. RBC Capital Markets has “Buy” rating and $67.0 target. On Tuesday, January 2 the rating was upgraded by JP Morgan to “Overweight”. On Thursday, January 25 the firm has “Buy” rating by Guggenheim given. On Wednesday, January 24 the stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given by BMO Capital Markets.

Abbott Laboratories (NYSE:ABT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: